Comparison of the Mesoscale Discovery and Luminex multiplex platforms for measurement of urinary biomarkers in a cisplatin rat kidney injury model

Journal of Pharmacological and Toxicological Methods

Volumn 69, Issue 2, 2014, Pages 196-204

  Pavkovic, Mira ^a   Riefke, Björn ^a   Gutberlet, Katrin ^a   Raschke, Marian ^a   Ellinger Ziegelbauer, Heidrun ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Luminex; MesoScale Discovery; Rat nephrotoxicity; Urinary protein biomarker

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; CLUSTERIN; CREATININE; GLUCOSE; GLUTATHIONE TRANSFERASE ALPHA; KIDNEY INJURY MOLECULE 1; METHAPYRILENE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLUCOSE URINE LEVEL; HISTOPATHOLOGY; KIDNEY INJURY; MALE; NEPHROTOXICITY; NONHUMAN; PROTEIN URINE LEVEL; RAT; URINE LEVEL; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; IMMUNOASSAY; KIDNEY DISEASE; PATHOLOGY; PROCEDURES; URINE; WISTAR RAT;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ANIMALS; BIOMARKERS; CISPLATIN; DISEASE MODELS, ANIMAL; IMMUNOASSAY; KIDNEY DISEASES; MALE; RATS; RATS, WISTAR;

EID: 84895929497     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.11.003     Document Type: Article

References (26)

1. Barabas K., Milner R., Lurie D., Adin C. Cisplatin: A review of toxicities and therapeutic applications. Veterinary and Comparative Oncology 2008, 6:1-18.
2. Bennett W.M. Drug nephrotoxicity: An overview. Renal Failure 1997, 19:221-224.
3. Chowdhury F., Williams A., Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. Journal of Immunological Methods 2009, 340:55-64.
4. Dieterle F., Perentes E., Cordier A., Roth D.R., Verdes P., Grenet O., et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nature Biotechnology 2010, 28:463-469.
5. EMA Final conclusions of the pilot joint EMEA/FDA VXDA experience on qualification of nephrotoxicity biomarkers [Doc.ref. EMEA/679719/2008 Rev. 1]. http://www.emea.europa.eu.
6. Fuchs T.C., Hewitt P. Preclinical perspective of urinary biomarkers for the detection of nephrotoxicity: What we know and what we need to know. Biomarkers in Medicine 2011, 5:763-779.
7. Gautier J.C., Riefke B., Walter J., Kurth P., Mylecraine L., Guilpin V., et al. Evaluation of novel biomarkers of nephrotoxicity in two strains of rat treated with Cisplatin. Toxicologic Pathology 2010, 38:943-956.
8. Harrison D.J., Kharbanda R., Cunningham D.S., McLellan L.I., Hayes J.D. Distribution of glutathione S-transferase isoenzymes in human kidney: Basis for possible markers of renal injury. Journal of Clinical Pathology 1989, 42:624-628.
9. Hidaka S., Kranzlin B., Gretz N., Witzgall R. Urinary clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries. Cell and Tissue Research 2002, 310:289-296.
10. Hoffmann D., Fuchs T.C., Henzler T., Matheis K.A., Herget T., Dekant W., et al. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 2010, 277:49-58.
11. Ichimura T., Bonventre J.V., Bailly V., Wei H., Hession C.A., Cate R.L., et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. The Journal of Biological Chemistry 1998, 273:4135-4142.
12. John-Baptiste A., Vitsky A., Sace F., Zong Q., Ko M., Yafawi R., et al. Comparison of 3 kidney injury multiplex panels in rats. International Journal of Toxicology 2012, 31:529-536.
13. Marrer E., Dieterle F. Impact of biomarker development on drug safety assessment. Toxicology and Applied Pharmacology 2010, 243:167-179.
14. Mishra J., Ma Q., Prada A., Mitsnefes M., Zahedi K., Yang J., et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. Journal of the American Society of Nephrology 2003, 14:2534-2543.
15. Muller P.Y., Dieterle F. Tissue-specific, non-invasive toxicity biomarkers: Translation from preclinical safety assessment to clinical safety monitoring. Expert Opinion on Drug Metabolism & Toxicology 2009, 5:1023-1038.
16. Ozer J.S., Dieterle F., Troth S., Perentes E., Cordier A., Verdes P., et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nature Biotechnology 2010, 28:486-494.
17. Pinches M., Betts C., Bickerton S., Burdett L., Thomas H., Derbyshire N., et al. Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: Gender and dosage differences. Toxicologic Pathology 2012, 40:522-533.
18. Rosenberg M.E., Silkensen J. Clusterin: Physiologic and pathophysiologic considerations. The International Journal of Biochemistry & Cell Biology 1995, 27:633-645.
19. Rozell B., Hansson H.A., Guthenberg C., Tahir M.K., Mannervik B. Glutathione transferases of classes alpha, mu and pi show selective expression in different regions of rat kidney. Xenobiotica 1993, 23:835-849.
20. Sasaki D., Yamada A., Umeno H., Kurihara H., Nakatsuji S., Fujihira S., et al. Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury. Biomarkers 2011, 16:553-566.
21. Sieber M., Hoffmann D., Adler M., Vaidya V.S., Clement M., Bonventre J.V., et al. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicological Sciences 2009, 109:336-349.
22. Swain A., Turton J., Scudamore C.L., Pereira I., Viswanathan N., Smyth R., et al. Urinary biomarkers in hexachloro-1:3-butadiene-induced acute kidney injury in the female Hanover Wistar rat; correlation of alpha-glutathione S-transferase, albumin and kidney injury molecule-1 with histopathology and gene expression. Journal of Applied Toxicology 2011, 31:366-377.
23. Tonomura Y., Tsuchiya N., Torii M., Uehara T. Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats. Toxicology 2010, 273:53-59.
24. Urbschat A., Obermuller N., Haferkamp A. Biomarkers of kidney injury. Biomarkers 2011, 16(Suppl. 1):S22-S30.
25. Vaidya V.S., Ozer J.S., Dieterle F., Collings F.B., Ramirez V., Troth S., et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nature Biotechnology 2010, 28:478-485.
26. Zhou Y., Vaidya V.S., Brown R.P., Zhang J., Rosenzweig B.A., Thompson K.L., et al. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicological Sciences 2008, 101:159-170.